Document is current
Any future updates will be listed below
-
Authors
Büyücek, Seyma
Schraps, Nina
Menz, Anne
Lutz, Florian
Chirico, Viktoria
Viehweger, Florian
Dum, David
Schlichter, Ria
Hinsch, Andrea
Fraune, Christoph
Bernreuther, Christian
Kluth, Martina
Hube-Magg, Claudia
Möller, Katharina
Reiswich, Viktor
Luebke, Andreas M.
Lebok, Patrick
Weidemann, Sören
Sauter, Guido
Lennartz, Maximilian
Jacobsen, Frank
Clauditz, Till S.
Marx, Andreas H.
Simon, Ronald
Steurer, Stefan
Burandt, Eike
Gorbokon, Natalia
Minner, Sarah
Krech, Till
Freytag, Morton
-
Funding
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
- License Information
-
More Information
Article History
Received: 15 October 2024
Accepted: 30 November 2024
First Online: 10 December 2024
Declarations
:
: The use of archived remnants of diagnostic tissues for manufacturing of TMAs and their analysis for research purposes as well as patient data analysis has been approved by local laws (HmbKHG, §12) and by the local ethics committee (Ethics commission Hamburg, WF-049/09). All work has been carried out in compliance with the Helsinki Declaration. Patient consent was waived due to local laws (HmbKHG, §12,1) that permit research with anonymized diagnostic left-over tissue samples.
: Not applicable.
: Conflict of interests The CLDN3 antibody clone HMV-309 was provided from ardoci GmbH (owned by a family member of GS).
